Durham, NC, United States of America

Cancer Advances, Inc.


USPTO Granted Patents = 8

% Expired Patents = 25.0



Forward Citations = 30

Loading Chart...
Loading Chart...

14 inventors (with patents filed for the assignee):

goldMedal Stephen Grimes (5 out of 22 patents)

silverMedal Jill P Smith (3 out of 18 patents)

bronzeMedal Allen E Cato (3 out of 9 patents)

4.  Lynda Sutton (3 out of 3 patents)

5.  Dov Michaeli (2 out of 5 patents)

6.  Brian Huber (2 out of 7 patents)

7.  Nicholas Osborne (2 out of 2 patents)

8.  Philip C Gevas (2 out of 11 patents)

9.  Martyn Caplin (1 out of 2 patents)

10.  Stephen L Karr (1 out of 12 patents)

11.  Susan A Watson (1 out of 2 patents)

12.  John Little (1 out of 2 patents)

13.  Lorraine McLoughlin (1 out of 2 patents)

14.  Teresa Phillips (1 out of 1 patent)

15.  Lorraine Mcloughlin (0 patent)


8 patents:

Company Overview
Cancer Advances, Inc. is a leading biotechnology company focused on developing innovative therapies for the treatment of various types of cancer. Our team of scientists and researchers are dedicated to advancing the field of oncology through cutting-edge research and clinical trials. With a portfolio of promising drug candidates, we are committed to bringing new hope to cancer patients worldwide.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

8 Patents

#90 in Durham, NC

#749 in North Carolina

#35,941 in US

Durham, NC (US)
Durham, NC, United States of America
Forward Citations = 30

14 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cancer Advances, Inc.. Retrieved from https://idiyas.com/company/cancer-advances

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…